646 related articles for article (PubMed ID: 16299289)
1. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.
Tada H; Aiba S; Shibata K; Ohteki T; Takada H
Infect Immun; 2005 Dec; 73(12):7967-76. PubMed ID: 16299289
[TBL] [Abstract][Full Text] [Related]
2. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture.
Uehara A; Yang S; Fujimoto Y; Fukase K; Kusumoto S; Shibata K; Sugawara S; Takada H
Cell Microbiol; 2005 Jan; 7(1):53-61. PubMed ID: 15617523
[TBL] [Abstract][Full Text] [Related]
3. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists.
Fritz JH; Girardin SE; Fitting C; Werts C; Mengin-Lecreulx D; Caroff M; Cavaillon JM; Philpott DJ; Adib-Conquy M
Eur J Immunol; 2005 Aug; 35(8):2459-70. PubMed ID: 16021602
[TBL] [Abstract][Full Text] [Related]
4. Chemically synthesized pathogen-associated molecular patterns increase the expression of peptidoglycan recognition proteins via toll-like receptors, NOD1 and NOD2 in human oral epithelial cells.
Uehara A; Sugawara Y; Kurata S; Fujimoto Y; Fukase K; Kusumoto S; Satta Y; Sasano T; Sugawara S; Takada H
Cell Microbiol; 2005 May; 7(5):675-86. PubMed ID: 15839897
[TBL] [Abstract][Full Text] [Related]
5. Enhanced induction of a histamine-forming enzyme, histidine decarboxylase, in mice primed with NOD1 or NOD2 ligand in response to various Toll-like receptor agonists.
Funayama H; Huang L; Asada Y; Endo Y; Takada H
Innate Immun; 2010 Aug; 16(4):265-72. PubMed ID: 19710098
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of NOD1 or NOD2 and TLR4 activation on mouse sickness behavior in relation to immune and brain activity markers.
Farzi A; Reichmann F; Meinitzer A; Mayerhofer R; Jain P; Hassan AM; Fröhlich EE; Wagner K; Painsipp E; Rinner B; Holzer P
Brain Behav Immun; 2015 Feb; 44():106-20. PubMed ID: 25218901
[TBL] [Abstract][Full Text] [Related]
7. Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo.
Cartwright N; Murch O; McMaster SK; Paul-Clark MJ; van Heel DA; Ryffel B; Quesniaux VF; Evans TW; Thiemermann C; Mitchell JA
Am J Respir Crit Care Med; 2007 Mar; 175(6):595-603. PubMed ID: 17234906
[TBL] [Abstract][Full Text] [Related]
8. NOD1 and NOD2 stimulation triggers innate immune responses of human periodontal ligament cells.
Jeon DI; Park SR; Ahn MY; Ahn SG; Park JH; Yoon JH
Int J Mol Med; 2012 Apr; 29(4):699-703. PubMed ID: 22218461
[TBL] [Abstract][Full Text] [Related]
9. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells.
Krumbiegel D; Zepp F; Meyer CU
Hum Immunol; 2007 Oct; 68(10):813-22. PubMed ID: 17961769
[TBL] [Abstract][Full Text] [Related]
10. Normal responses to specific NOD1-activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease.
van Heel DA; Hunt KA; Ghosh S; Hervé M; Playford RJ
Eur J Immunol; 2006 Jun; 36(6):1629-35. PubMed ID: 16637007
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of TLR-mediated innate immune responses by peptidoglycans through NOD signaling.
Takada H; Uehara A
Curr Pharm Des; 2006; 12(32):4163-72. PubMed ID: 17100619
[TBL] [Abstract][Full Text] [Related]
12. RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs.
Park JH; Kim YG; McDonald C; Kanneganti TD; Hasegawa M; Body-Malapel M; Inohara N; Núñez G
J Immunol; 2007 Feb; 178(4):2380-6. PubMed ID: 17277144
[TBL] [Abstract][Full Text] [Related]
13. Analgesic effects of chemically synthesized NOD1 and NOD2 agonists in mice.
Sato T; Shikama Y; Shimauchi H; Endo Y; Takada H
Innate Immun; 2011 Feb; 17(1):54-9. PubMed ID: 20083500
[TBL] [Abstract][Full Text] [Related]
14. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines.
Uehara A; Fujimoto Y; Fukase K; Takada H
Mol Immunol; 2007 May; 44(12):3100-11. PubMed ID: 17403538
[TBL] [Abstract][Full Text] [Related]
15. Nod2 and Rip2 contribute to innate immune responses in mouse neutrophils.
Jeong YJ; Kang MJ; Lee SJ; Kim CH; Kim JC; Kim TH; Kim DJ; Kim D; Núñez G; Park JH
Immunology; 2014 Oct; 143(2):269-76. PubMed ID: 24766550
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic Differences in Primary Murine Microglia Treated with NOD1, NOD2, and NOD1/2 Agonists.
Wasmuth S; Jalilvand TV; Laffer B; Busch M; Bauer D; Langmann T; Thanos S; Kasper M; Heiligenhaus A
J Mol Neurosci; 2020 Apr; 70(4):600-609. PubMed ID: 31907866
[TBL] [Abstract][Full Text] [Related]
17. Expression of TRAF6 and pro-inflammatory cytokines through activation of TLR2, TLR4, NOD1, and NOD2 in human periodontal ligament fibroblasts.
Tang L; Zhou XD; Wang Q; Zhang L; Wang Y; Li XY; Huang DM
Arch Oral Biol; 2011 Oct; 56(10):1064-72. PubMed ID: 21457942
[TBL] [Abstract][Full Text] [Related]
18. Human fetal membranes generate distinct cytokine profiles in response to bacterial Toll-like receptor and nod-like receptor agonists.
Hoang M; Potter JA; Gysler SM; Han CS; Guller S; Norwitz ER; Abrahams VM
Biol Reprod; 2014 Feb; 90(2):39. PubMed ID: 24429216
[TBL] [Abstract][Full Text] [Related]
19. TLR8 combined withTLR3 or TLR4 agonists enhances DC-NK driven effector Tc1 cells.
Nouri-Shirazi M; Tamjidi S; Nourishirazi E; Guinet E
Immunol Lett; 2018 Jan; 193():58-66. PubMed ID: 29103998
[TBL] [Abstract][Full Text] [Related]
20. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells.
Re F; Strominger JL
J Immunol; 2004 Dec; 173(12):7548-55. PubMed ID: 15585882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
